Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes

被引：12

作者：

Bannerji, Rajat ^{[1
]}

Arnason, Jon E. ^{[2
]}

Advani, Ranjana ^{[3
]}

Brown, Jennifer R. ^{[4
]}

Allan, John N. ^{[5
]}

Ansell, Stephen M. ^{[6
]}

Barnes, Jeffrey ^{[7
]}

O'Brien, Susan M. ^{[8
]}

Chavez, Julio C. ^{[9
]}

Duell, Johannes ^{[10
]}

Lowy, Israel ^{[11
]}

Charnas, Robert ^{[11
]}

Sternberg, David ^{[11
]}

Ambati, Srikanth ^{[11
]}

Adriaens, Lieve ^{[12
]}

Ufkin, Melanie ^{[11
]}

Yan, Xiaoyu ^{[11
]}

Li, Jingjin ^{[12
]}

Navarro, Mark ^{[11
]}

Gasparini, Peter ^{[11
]}

Jankovic, Vladimir ^{[11
]}

Fiaschi, Nathalie ^{[11
]}

Zhang, Wen ^{[11
]}

Hamon, Sara ^{[11
]}

Thurston, Gavin ^{[11
]}

Topp, Max S. ^{[10
]}

机构：

[1] Canc Inst New Jersey, New Brunswick, NJ USA

[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[3] Stanford Univ, Stanford, CA 94305 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Weill Cornell Med, Div Hematol & Oncol, New York, NY USA

[6] Mayo Clin, Div Hematol, Rochester, MN USA

[7] Massachusetts Gen Hosp, Boston, MA 02114 USA

[8] Univ Calif Irvine, Irvine, CA USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[10] Univ Hosp Wurzburg, Wurzburg, Germany

[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[12] Regeneron Pharmaceut Inc, Basking Ridge, NJ USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-113328

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1690

引用

页数：5

共 50 条

[1] Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Bannerji, Rajat
Allan, John N.
Arnason, Jon E.
Brown, Jennifer R.
Advani, Ranjana H.
Barnes, Jeffrey A.
Ansell, Stephen M.
O'Brien, Susan M.
Chavez, Julio
Duell, Johannes
David, Kevin A.
Martin, Peter
Joyce, Robin M.
Charnas, Robert
Ambati, Srikanth R.
Adriaens, Lieve
Ufkin, Melanie
Zhu, Min
Li, Jingjin
Gasparini, Peter
Ibrahim, Anfal
Jankovic, Vladimir
Fiaschi, Nathalie
Aina, Olulanu
Zhang, Wen
Deering, Raquel P.
Hamon, Sara
Thurston, Gavin
Murphy, Andrew J.
Weinreich, David M.
Yancopoulos, George D.
Lowy, Israel
Sternberg, David
Topp, Max S.
BLOOD, 2019, 134
[2] A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Topp, Max S.
Duell, Johannes
Li, Jingjin
Jankovic, Vladimir
Lowy, Israel
Sternberg, David
Adriaens, Lieve
Peterman, Mary
Ambati, Srikanth R.
Bannerji, Rajat
BLOOD, 2019, 134
[3] A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Kim, Tae Min
Alonso, Arancha
Prince, Miles
Taszner, Michal
Cho, Seok-Goo
Stevens, Don A.
Poon, Michelle
Lim, Francesca
Le Gouill, Steven
Carpio, Cecilia
Keating, Mary-Margaret
Adriaens, Lieve
Ufkin, Melanie
Sabir, Ayesha
Li, Jingjin
Jankovic, Vladimir
Zhu, Min
Brouwer-Visser, Jurriaan
Leng, Siyang
Sirulnik, L. Andres
Chaudhry, Aafia
Ambati, Srikanth R.
Seog, Kim Won
BLOOD, 2020, 136
[4] Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
Max S. Topp
Herbert Eradat
Axel Florschütz
Andreas Hochhaus
Tomasz Wrobel
Jan Walewski
Wanda Knopinska-Posluszny
Abraham S. Kanate
Ewa Lech-Maranda
Uta Brunnberg
Surya Chitra
Tina G. Nielsen
Gila Sellam
Mahesh Shivhare
Izidore S. Lossos
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 811 - 817
[5] PHARMACOKINETICS AND EXPOSURE-RESPONSE FOR REGN1979, A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA.
Yang, F.
Zhu, M.
Toroghi, M.
Putluri, D.
Yan, H.
Davis, J.
DiCioccio, A.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S120 - S120
[6] Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma
Yuen, Sam
Phillips, Tycel J.
Bannerji, Rajat
Marlton, Paula
Gritti, Giuseppe
Seymour, John F.
Johnston, Anna
Arthur, Christopher
Dodero, Anna
Sharma, Sunil
Hirata, Jamie
Musick, Lisa
Flowers, Christopher R.
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1281 - 1289
[7] Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy
Bannerji, Rajat
Advani, Ranjana H.
Brown, Jennifer R.
Arnason, Jon E.
Barnes, Jeffrey A.
Allan, John N.
Ansell, Stephen M.
O'Brien, Susan M.
Chavez, Julio C.
Adriaens, Lieve
Ufkin, Melanie
Kostic, Ana
Paccaly, Anne Josee
Gao, Bo
Lowy, Israel
Sternberg, David
Topp, Max S.
BLOOD, 2017, 130
[8] Activity and safety of ibrutinib and durvalumab in patients with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL)
Herrera, A.
Goy, A.
Mehta, A.
Ramchandren, R.
Pagel, J.
Svoboda, J.
Guan, S.
Hill, J.
Kwei, K.
Liu, E.
Phillips, T.
EUROPEAN JOURNAL OF CANCER, 2018, 103 : E17 - E18
[9] Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 X anti-CD3 bispecific diabody
Xiong, DS
Xu, YF
Liu, HZ
Peng, H
Shao, XF
Lai, ZZ
Fan, DM
Yang, M
Han, JL
Xie, Y
Yang, CZ
Zhu, ZQ
CANCER LETTERS, 2002, 177 (01) : 29 - 39
[10] Maintenance therapy using the anti-CD20 antibody Rituximab in patients with B-cell non-Hodgkin lymphoma
Neumann, F
Martin, S
Kronenwett, R
Fischer, C
Kondakci, M
Kobbe, G
Gattermann, N
Haas, R
BLOOD, 2003, 102 (11) : 298B - 298B

← 1 2 3 4 5 →